RBC Capital Reiterates Outperform on Legend Biotech, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for Legend Biotech (NASDAQ:LEGN) and maintained a price target of $86.
September 27, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Legend Biotech, maintaining a price target of $86, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a high price target by RBC Capital suggests positive sentiment and confidence in Legend Biotech's future performance. This is likely to have a positive short-term impact on the stock price as it reflects analyst confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100